文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

如何治疗Wiskott-Aldrich综合征

How I treat Wiskott-Aldrich syndrome.
PubMed 文献 · Blood · 2025-01-01

本文基于近期发表的证据,讨论Wiskott-Aldrich综合征(WAS)的保守治疗与根治性治疗方法。疾病严重程度高度可变,疾病进展概率取决于基因变异类型,支持早期诊断和个体化治疗策略。较轻病例(曾称XLT)接受支持治疗,重型病例接受标准异基因造血细胞移植(HCT)或临床试验中的基因治疗(GT)。HCT和GT的进展以及即使XLT患者也存在严重免疫并发症风险的新认识,提示大多数年轻WAS患者应在诊断时接受潜在根治性治疗。

要点

  • WAS疾病进展概率取决于基因变异类型,支持早期诊断和个体化治疗策略。
  • 大多数年轻WAS患者应在诊断时接受潜在根治性治疗(HCT或GT)。
  • 建议停用XLT术语,因其暗示轻度且无并发症的疾病,而并非常态。

核心结论

  • 大多数年轻WAS患者应在诊断时接受潜在根治性治疗。
  • 少数携带较轻变异的老年患者可保守治疗,除非出现危及生命的自身免疫或恶性并发症。
  • 建议停用XLT术语,按个体基因型、疾病严重程度和临床病程制定治疗。

研究设计与样本

  • 本文为基于近期发表证据的综述,讨论WAS的保守和根治性治疗方法。

主要发现

  • WAS疾病严重程度高度可变,疾病进展概率取决于基因变异类型。
  • 较轻病例(曾称XLT)接受支持治疗,重型病例接受标准异基因HCT或临床试验中的GT。
  • 即使XLT患者也存在严重免疫并发症风险。

临床怎么用

  • 大多数年轻WAS患者应在诊断时接受潜在根治性治疗。
  • 少数携带较轻变异的老年患者可保守治疗,除非出现危及生命的自身免疫或恶性并发症。
  • 定期监测和积极管理对预防不可逆并发症至关重要。
  • 建议停用XLT术语,按个体基因型、疾病严重程度和临床病程制定治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder, characterized by thrombocytopenia, eczema, recurrent infections, autoimmunity, and malignancy. Here, we discuss current conservative and definitive approaches to treating WAS, based on recently published evidence. Disease severity in WAS is highly variable. Recent studies confirm that the probability of disease progression depends on the type of genetic variant, supporting early diagnosis and tailored treatment strategies. Milder cases, historically termed X-linked thrombocytopenia (XLT), received supportive care, whereas severe cases were referred for standard allogeneic hematopoietic cell transplantation (HCT) or gene therapy (GT) in clinical trials. Advances in HCT and GT, together with recent knowledge that even patients with XLT are at risk for severe immune complications, suggest that most young patients with WAS should be offered a potentially curative approach at diagnosis. Older patients with a small subset of milder variants may be treated conservatively unless they develop life-threatening autoimmune or malignant complications; regular monitoring and proactive management are critical to preventing irreversible complications. We recommend discontinuing the term XLT as it implies a mild and uncomplicated disease, which is not the norm, and instead tailor treatment for all patients with WAS to their individual genetic profile, disease severity, and clinical course.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Vallée TC, Albert MH, Pai SY, et al. How I treat Wiskott-Aldrich syndrome. Blood. 2025. PMID: 40209058. doi:10.1182/blood.2024026288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。